Literature DB >> 9231754

Parathyroid hormone (PTH 1-34) regulation of rat osteocalcin gene transcription.

X P Yu1, S Chandrasekhar.   

Abstract

Osteocalcin (OC) is a bone-specific extracellular matrix protein expressed by mature osteoblasts during late stages of differentiation. Previous studies have shown that forskolin, an activator of adenylate cyclase, stimulated OC production. Because PTH has been shown to activate several intracellular signal transduction pathways including cAMP, inositol phosphate and intracellular calcium mobilization, we investigated whether PTH action on cAMP accumulation leads to OC promoter activation. The rat OC promoter (1095 bp) was cloned into the promoterless luciferase gene reporter vector. The transcriptional activity of the rat OC promoter was evaluated after transfection of SaOS-2, an osteosarcoma cell line, with the OC promoter followed by treatment with PTH. Maximal OC promoter activity was observed within 4-8 h after the addition of 10(-8) M PTH, whereas very little induction was seen after 24 and 48 h of treatment. The induction of OC promoter activity by PTH was concentration dependent. PTH analogs (PTH 1-84, PTH 1-34, and PTH 1-31) that stimulate intracellular cAMP accumulation, induced OC promoter activity, whereas other PTH analogs (PTH 3-34, PTH 7-34, PTH 13-34, and PTH 53-84) that do not stimulate cAMP production had no effect on OC promoter activation. Furthermore, PTH activation of the OC promoter was significantly enhanced in the presence of 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor. Inactivation of cAMP-dependent protein kinase A activity by either a selective protein kinase A inhibitor, H-89 (N-[2-(p-bromocinnamylamino)ethyl]-5 isoquinolinesulfonamide), or antisense oligonucleotide directed against the regulatory subunit of cAMP-dependent protein kinase A, led to a corresponding loss of OC promoter activation by PTH. 5' deletion analysis of the OC promoter demonstrated that the promoter (1095 bp) exhibited the greatest response to PTH, whereas the -198 bp construct of the OC promoter, containing only one cAMP response element and OC box, was no longer responsive. The constructs with further deletions (-120, -92, and -74) retained PTH responsiveness, but to a lesser extent. In summary, our results indicate that PTH activation of the OC promoter is a rapid event and mediated by the cAMP-dependent protein kinase A pathway. Although the novel cAMP response region overlapping the OC box is required for activation, full activation may require several cis-acting cAMP response elements or other response elements.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231754     DOI: 10.1210/endo.138.8.5315

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Regulation of PTH/PTH-related protein receptor expression by endogenous PTH-related protein in the rat osteosarcoma cell line ROS 17/2.8.

Authors:  P Du; P K Seitz; C W Cooper
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

2.  The basic helix loop helix transcription factor Twist1 is a novel regulator of ATF4 in osteoblasts.

Authors:  Theodora E Danciu; Yan Li; Amy Koh; Guozhi Xiao; Laurie K McCauley; Renny T Franceschi
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

3.  Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development.

Authors:  B Lanske; M Amling; L Neff; J Guiducci; R Baron; H M Kronenberg
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

4.  Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.

Authors:  S Okuno; E Ishimura; N Tsuboniwa; K Norimine; K Yamakawa; T Yamakawa; S Shoji; K Mori; Y Nishizawa; M Inaba
Journal:  Osteoporos Int       Date:  2012-05-12       Impact factor: 4.507

5.  Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression.

Authors:  Shibing Yu; Renny T Franceschi; Min Luo; Xiaoyan Zhang; Di Jiang; Yumei Lai; Yu Jiang; Jian Zhang; Guozhi Xiao
Journal:  Endocrinology       Date:  2008-01-10       Impact factor: 4.736

6.  Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.

Authors:  Eric Bonnet; Jean-Bernard Ruidavets; Anne Genoux; Laurence Mabile; Florian Busato; Martine Obadia; François Prévoteau; Bruno Marchou; Patrice Massip; Fabrice Marion-Latard; Cyrille Delpierre; Jacques Bernard; Bertrand Perret
Journal:  BMC Infect Dis       Date:  2013-06-28       Impact factor: 3.090

7.  Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone.

Authors:  Shibing Yu; Renny T Franceschi; Min Luo; Jie Fan; Di Jiang; Huiling Cao; Tae-Geon Kwon; Yumei Lai; Jian Zhang; Kenneth Patrene; Kurt Hankenson; G David Roodman; Guozhi Xiao
Journal:  PLoS One       Date:  2009-10-23       Impact factor: 3.240

8.  In vivo determination of vitamin d function using transgenic mice carrying a human osteocalcin luciferase reporter gene.

Authors:  Tomoko Nakanishi; Rumiko Saito; Makoto Taniguchi; Haruka Oda; Atsumi Soma; Mayu Yasunaga; Mariko Yamane; Kenzo Sato
Journal:  Biomed Res Int       Date:  2013-03-27       Impact factor: 3.411

9.  A cross-sectional study of osteocalcin and body fat measures among obese adolescents.

Authors:  Carine M Lenders; Phillip D K Lee; Henry A Feldman; Darrell M Wilson; Stephanie H Abrams; Stephen E Gitelman; William J Klish; Marcia S Wertz; George A Taylor; Richard T Alongi; Tai C Chen; Michael F Holick
Journal:  Obesity (Silver Spring)       Date:  2013-04       Impact factor: 5.002

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.